Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nilotinib study in inoperable PVNS/TGCT
NL-OMON36562Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in tenosynovial giant cell tumor (TGCT), sponsored by Leiden University Medical Center. Primary endpoint: Non-progression rate at 12 weeks. Started Mar 2011; status: active, not recruiting.
02
Drugs
nilotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NL-OMON36562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36562.